LianBio
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which … Read more
LianBio (LIANY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 0.536x
Based on the latest financial reports, LianBio (LIANY) has a cash flow conversion efficiency ratio of 0.536x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($311.52 Million) by net assets ($581.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LianBio - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how LianBio's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
LianBio Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LianBio ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
-0.438x |
|
Radhika Jeweltech Limited
NSE:RADHIKAJWE
|
0.003x |
|
Wellysun Inc
TW:6988
|
0.073x |
|
Rocky Mountain Chocolate Factory
NASDAQ:RMCF
|
-0.206x |
|
Icape Holding
PA:ALICA
|
0.235x |
|
Eden Research plc
PINK:EDNSF
|
-0.066x |
|
Goa Carbon Limited
NSE:GOACARBON
|
-0.158x |
|
OCR Group Bhd
KLSE:7071
|
-0.107x |
Annual Cash Flow Conversion Efficiency for LianBio (2019–2024)
The table below shows the annual cash flow conversion efficiency of LianBio from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $62.87 Million | $3.75 Million | 0.060x | -86.62% |
| 2023-09-30 | $581.20 Million | $258.94 Million | 0.446x | +232.06% |
| 2022-09-30 | $293.65 Million | $-99.07 Million | -0.337x | +20.40% |
| 2021-09-30 | $387.33 Million | $-164.17 Million | -0.424x | -8.53% |
| 2020-09-30 | $251.72 Million | $-98.31 Million | -0.391x | -33.91% |
| 2019-09-30 | $40.18 Million | $-11.72 Million | -0.292x | -- |